Increased platelet aggregation and activation in peripheral arterial disease

European Journal of Vascular and Endovascular Surgery

Volumn 25, Issue 1, 2003, Pages 16-22

  Robless, P A ^a   Okonko, D ^a   Lintott, P ^a   Mansfield, A O ^a   Mikhailidis, D P ^b   Stansby, G P ^c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Activation; Aspirin; Peripheral arteries; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTIGEN; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; NITRATE; PAC 1 ANTIGEN; PADGEM PROTEIN; TICLOPIDINE; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PAC1 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANTIGEN BINDING; ARTERY DISEASE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CONTROLLED STUDY; DRUG INDICATION; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEG ARTERY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; BLOOD; COMPARATIVE STUDY; LEG; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PHYSIOLOGY; THROMBOCYTE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; AORTIC ANEURYSM, ABDOMINAL; BLOOD PLATELETS; CAROTID ARTERY DISEASES; FEMALE; FLOW CYTOMETRY; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; P-SELECTIN; PERIPHERAL VASCULAR DISEASES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN-TYROSINE-PHOSPHATASE;

EID: 0037270535     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1794     Document Type: Article

References (45)

1. FURMAN M, BENOIT S, BARNARD M et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31: 352-358.
2. AULT K, CANNON C, MITCHELL J et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial: thrombolysis in myocardial infarction. J Am Coll Cardiol 1999; 33: 634-639.
3. GRAU A, RUF A, VOGT A et al. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischaemia. Thromb Haem 1998; 80: 298-301.
4. ZELLER J, TSCHOEPE D, KESSLER C. Circulating platelets show increased activation in patients with acute cerebral ischaemia. Thromb Haem 1999; 81: 373-377.
5. THAULOW E, ERIKSSEN J, SANDVIK L, STORMORKEN H, COHN P. Blood platelet count and fuction are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-617.
6. TRIP M, CATS V, VAN CAPELLE F, VREEKEN J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 31: 1549-1554.
7. BARRADAS M, STANSBY G, MIKHAILIDIS D. Diminished platelet yield and enhanced platelet aggregability in platelet rich plasma of peripheral vascular disease patients. Int Angiol 1994; 13: 202-207.
8. WALTERS T, MITCHELL D, WOODS R. Low dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg 1993; 80: 1266-1268.
9. DORMANDY J, HEECK L, VIG S. Lower extremity arteriosclerosis as a reflection of a systemic process: Implications for concommitant coronary and carotid disease. Sem Vasc Surg 1999; 12: 118-122.
10. LENG G, LEE A, FOWKES F et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral artery disease in the general population. Int J Epidemiol 1996; 25: 1172-1181.
11. CRIQUI M, DENENBERG J, LANGER R, FRONEK A. The epidemiology of peripheral arterial disease: the importance of identifying the population at risk. Vasc Med 1997; 2: 221-226.
12. LENG G, FOWKES F, LEE A, DUNBAR J, HOUSLEY E, RUCKLEY C. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313: 1440-1444.
13. CAPRIE Steering Committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1338.
14. MIKHAILIDIS D, JAGROOP I. Is clopidogrel markedly superior to aspirin in patients with peripheral vascular disease? Platelets 1998;9:273-278.
15. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
16. ROBLESS P, MIKHAILIDIS D, STANSBY G. A systematic review of antiplatelet therapy for prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88: 787-800.
17. BARNETT H, KASTE M, MELDRUM B, ELIASZIW M. Aspirin dose in stroke prevention: Beautiful hypothesis slain by ugly facts. Stroke 1996;27:588-592.
18. BARRADAS M, STANSBY G, MIKHAILIDIS D. Naftidrofuryl and Aspirin on platelet aggregation in peripheral vascular disease. In vivo 1993; 7: 543-548.
19. REININGER C, GREINACHER A, GRAF J, LASSER R, STECKMEIER B, SCHWEIBERER L. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res 1996; 81: 641-649.
20. SMOUT J, STANSBY G. Aspirin resistance. Br J Surg 2002; 89: 4-5.
21. GEORGE J, SHATTIL S. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324: 27-39.
22. SCHMITZ G, ROTHE G, RUF A et al. European working group on cell cycle analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-896.
23. SHATTIL S, CUNNINGHAM M, HOXIE J. Detection of activated platelets in whole blood using activation dependant monoclonal antibodies and whole blood flow cytometry. Blood 1987; 70: 307-315.
24. ROBLESS P, TEGOS T, OKONKO D et al. Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets 2002; 13: 231-239.
25. MICHELSON A, BARNARD M, HECHTMAN H et al. In vivo tracking of platelets: circulating degranulating platelets rapidly lose surface P-selectin but continue to circulate and function. In: Proceedings of the National Academy of Sciences of the United States of America 1996; 11877-11882.
26. TSCHOEPE D, SCHULTHEIB M, KOLAROV P et al. Platelet membrane activation markers are predictive for acute ischaemic events after PTCA. Circulation 1993; 88: 37-42.
27. ISHIWATA S, TUKADA T, TOSHIYASU T, NAKANISHI S, NISHIYAMA S, SEKI A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997; 133: 387-392.
28. IKEDA H, TAKAJO Y, ICHIKI K et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995; 92: 1693-1696.
29. KAIKITA K, OGAWA H, YASUE H et al. Soluble P-selectin is released into the coronary circulation after coronary spasm. Circulation 1995; 92: 1726-1730.
30. BLANN A, DABROTOVA M, KUBISZ P, MCCOLLUM C. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995; 74: 626-630.
31. GALT S, MCDANIEL M, AULT K, MITCHELL J, CRONENWETT J. Flow cytometric assessment of platelet function in patients with peripheral arterial occlusive disease. J Vasc Surg 1991; 16: 747-756.
32. MICHELSON A. Flow cytometry: a clinical test of platelet function. Blood 1996; 87: 4925-4936.
33. VALLES J, SANTOS M, AZNAR J et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality. Circulation 1998; 97: 350-355.
34. RUGGERI Z. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997; 78: 611-616.
35. BARRADAS M, MIKHAILIDIS D. Serotonin, histamine and platelets in vascular disease with specific reference to peripheral vascular disease. Braz J Med Biol Res 1992; 25: 1063-1076.
36. DAVI G, GRESELE P, VIOLI F et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo: evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
37. SCHULTHEIß H, TSCHOEPE D, ESSER J et al. Large platelets continue to circulate in an activated state after myocardial infarction. Eur J Clin Invest 1994; 24: 243-247.
38. TSCHOEPE D, ROESEN P, ESSER J et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Haemost 1991; 13: 857-862.
39. WOLF R, PENG J, FRIESE P, GILMORE L, BURSTEIN S, DALE G. Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost 1997; 78: 1505-1509.
40. AWTRY E, LOSCALZO J. Aspirin. Circulation 2000; 101: 1206-1218.
41. SAMAMA C, BONNIN P, BONEAU M et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemost 1992; 68: 500-505.
42. HERBERT J, TISSINIER A, DEFREYN G, MAFFRAND J. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 1993; 13: 1171-1179.
43. LEON M, BAIM D, POPMA J et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med 1998; 339: 1665-1671.
44. GOODS C, AL-SHAIBI K, LIU M et al. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol 1996; 78: 1042-1044.
45. MEHTA S, YUSUF S, PETERS R et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.